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ABSTRACT
Human CD34+ cells have been shown to retain long-term hematopoietic engrafting potential in preclinical and clin-
ical studies. However, recent studies of human and murine CD34- stem cells suggest that these are functionally
important early progenitors. Using autologous transplantation, we investigated whether canine CD34+ and CD34-
marrow cells could be transduced and give rise to long-term hematopoiesis. CD34+Lin-and CD34Lin- cell popula-
tions purified by fluorescence-activated cell sorting were separately cocultivated with retroviral vectors LN
(CD34+Linl and LNY (CD34Linl, which carry the neomycin (neo) gene. After myeloablative total bodyirradiation
(920 cGy), 3 dogs received transplants of both CD34+Lin- cells and CD34""Lin- cells and 2 dogs received only
CD34Lin- cells. Untransduced autologous marrow cells were given to ensure hematopoietic recovery. Using CFU-C
assays, transduction efficiencies of CD34+Lin- cells ranged from 6% to 18% with no CFU-C formation from
CD34Lin- cells. PCR-based detection of the neogene from WBCs was used to detect transduced cells weekly after
transplantation. Additional PCR studies in 3 dogs given both CD34+Lin- and CD34Lin- cells were performed on
monocytes, granulocytes, and T cells (2 dogs, one at 7.5 months and the other at 9 months) and granulocytes (1 dog
at 12 months). LN was detected up to 12 months posttransplantation in WBCs and mono-myeloid and lymphoid
populations from 3 dogs receiving transplants of transduced CD34+Lin- cells. LNY was not detected at any time
after transplantation in S dogs that received transduced CD34Lin- cells. Whereas canine CD34+Lin- marrow ceDs
contributed to long-term multilineage hematopoiesis, progeny of CD34Lin- progenitor ceDs were not detected
after transplantation in these experiments.
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INTRODUCTION
Hematopoietic cell transplantation using populations
enriched for CD34+cells has potentially important applica-
tions in the treatment of malignant and nonmalignant dis-
eases. CD34 selection may allow purging of tumor cells
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from autografts and removal of T cells for protection from
graft-versus-host disease (GVHD) after allografting. More-
over, the enrichment of CD34+cells may have an important
role in gene transduction procedures that target hemato-
poietic progenitors. Successful transplantation of hemato-
poietic progenitor cells has been demonstrated with marrow
or mobilized peripheral blood enriched for cells expressing
the cell surface glycoprotein CD34 [1-5]. In vitro and in
vivo animal studies have shown that enriched CD34+ mar-
row cells of different species can give rise to multiple blood-
cell lineages and may provide long-term hematopoiesis,
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suggesting that CD34 could be regarded as a cell surface
marker of primitive hematopoietic stem cells [6-8]. How-
ever, interpretation of autografting studies is confounded by
the recovery of hematopoiesis from endogenous stem cells
that survive what are considered to be myeloablative condi-
tioning regimens. Recent studies have challenged the idea
that CD34 is a marker of the most primitive hematopoietic
stem cell. Osawa et al. showed that the injection of a single
primitive adult mouse bone marrow cell, isolated from the
CD34-/ lowLin- compartment, could result in long-term
reconstitution of the Iympho-hematopoietic system [9].
Goodell et al. showed that in human and nonhuman primate
bone marrow, a cell population expressing low or unde-
tectable levels of CD34 antigen and defined as a side popu-
lation by exclusion of Hoechst 33342 dye became CD34+
after 5 weeks of culture on bone marrow stromal cells
[10,11]. Bhatia et aI. purified a human distinct cell popula-
tion without detectable surface markers usually associated
with stem cells, such as HLA-DR, Thy-I, and CD34, that
was capable of multilineage repopulation in NOD/SCID
mice [12]. More recently, Sato et aI. demonstrated that the
expression of CD34 on murine marrow hematopoietic pro-
genitor cells is reversible and may reflect a different state of
activation and/or cycling of the same cell [13]. Finally,
Nakamura et a1. induced the ex vivo differentiation of
human CD34- hematopoietic cells into CD34+ cells with
long-term multilineage repopulating ability on a murine
bone marrow stromal cell layer [14].Thus, the exact pheno-
type of the most primitive hematopoietic stem cell, which
has possible implications for clinical stem cell transplanta-
tion, remains uncertain [15].
In previous studies, we found that canine CD34+ cells
were phenotypically and functionally similar to human
CD34+cells [16,17].
To further elucidate in vivo functions of canine hemato-
poietic progenitors, we designed experiments using auto-
logous transplantation of gene-marked progenitor cell
populations. Highly purified canine CD34+Lin- and
CD34-Lin- marrow cellswere separately cocultivated in vitro
with retroviral vectors and reinfused into the animals after
myeloablative total body irradiation. The dogs were then
studied for evidence of hematopoietic reconstitution from the
2 cell fractions. The main objectives of this study were to
evaluate (1) whether short-term and long-term hematopoietic
reconstitution could occur from both CD34+ and CD34-
canine marrow cell populations, and (2) if these populations
could generate multilineage hematopoietic recovery.
MATERIAL AND METHODS
Animals
Beagle dogs were raised at the Fred Hutchinson Cancer
Research Center (FHCRC) or obtained from the Depart-
ment of Agriculture. Dogs were immunized against rabies,
leptospirosis, hepatitis, papiIIomavirus, and parvovirus and
observed for disease for at least 2 months before entering
the study. Research was performed according to the guide-
lines for Laboratory Animal Facilities and Care prepared by
the National Academy of Sciences, National Research
Council. The study was approved by the Institutional Ani-
mal Care and Use Committee of the FHCRC.
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Total Body Irradiation and Supportive Care
All dogs were conditioned for autologous transplant
with 920 cGy total body irradiation (fBI) delivered as a sin-
gle dose at 7 cGy per minute from 2 opposing 60Co sources
[18]. Transduced CD34+Lin- and CD34-Lin- cells were
reinfused over 1 to 3 minutes within 24 hours after TBI. All
dogs also received untransduced cryopreserved autologous
bone marrow or untransduced enriched CD34+marrow cells
to ensure hematopoietic recovery. Supportive care consisted
of oral and systemic antibiotics, intravenous fluids with elec-
trolytes, and blood transfusions. Complete blood counts
were obtained before transplantation, then daily until stable
engraftment, and weekly thereafter. Hematopoietic growth
factors were not administered throughout the study. Neu-
trophil engraftment was defined as the first of 3 consecutive
days with a neutrophil count ~500/JlL and platelet engraft-
ment as the first of 3 consecutive days with a platelet count
~O,OOO/JlL for 3 days after the postirradiation nadir.
Purification of CD34+Lin- and CD34-Lin- Marrow Cells
Bone marrow was aspirated from both femora of anes-
thetized dogs using standard techniques. Ficoll-separated
marrow cells were enriched as previously described [17,19].
Briefly, cells were labeled with biotinylated monoclonal
antibody IH6 (immunoglobulin G-l [IgG-l] anti-canine
CD34) [16] at 4°C for 15 minutes. Cells were washed twice
and then incubated with streptavidin-conjugated microbeads
for 15 minutes at 4°C, washed again, and then separated
using an immunomagnetic column technique (Miltenyi
Biotec, Auburn, CA). Eluted CD34+ and flow-through
CD34- cell fractions were then stained with directly fluores-
ceinated monoclonal antibodies CDI4-FITC (fuk-4, Dako,
AlS Denmark) and CAI7.6F9-FITC (murine IgG2a recog-
nizing canine CD3) against monocytoid and lymphoid lin-
eage markers, respectively, and streptavidin phycoerythrin
(PE) (Southern Biotechnology, Birmingham, AL). Cells were
filtered with a 70-Jlffi.cell strainer (Falcon, Beeton Dickinson
Labware, Lincoln Park, NJ) and adjusted to a final concen-
tration of 2 to 4 x 106/mL with DNAase (Boehringer
Mannheim, Mannheim, Germany) at 1000 U/mL in
Iscove/20% fetal bovine serum (FBS). Two cell populations,
1 positive and 1 negative for CD34 and both negative for
CD14 and CD3, were purified by cell sorting using a Van-
tage fluorescence-activated cell sorter (FACS) (Becton Dick-
inson, San Jose, CA), and defined as CD34+Lin- and
CD34-Lin- cell populations, respectively. After sorting, sam-
ples from the sorted fractions were analyzed for purity. List
mode data were analyzed using Winlist (Verity Software
House, Topsham, ME), and gates were set on forward and
side light scatter to exclude platelets and cell debris.
Transduction of CD34+Lln- and CD34-Lln- Marrow
Cells
CD34+Lin- and CD34-Lin- cell populations were sepa-
rately transduced with the retroviral vectors LN and LNY
[20,21], respectively, using cocultivation techniques as previ-
ously described [22,23]. Briefly, cell populations were added
to 75_~2 canted-neck flasks (Corning, Corning, NY) con-
taining irradiated PG 13 (GALV-pseudotype)-based packag-
ing cells in the presence of 50 ng/mL each of human FLT3
ligand (FLT3L), recombinant canine stem cell factor
Canine CD34+Lin-MarTOw Cells Transduced With Retroviral ~etors
Table I. CellYields ofCD34+Lin- andCD3-FLin- Marro»Cells After FACSandAfter 2Days ofCocultivation onIrradiated PG13-Based Packaging Cells-
C034+L1n-After FACS
C034+L1n-After C034-a.ln- After
C034-L1n- After FACS Cocultlvatlon Cocultlvatlon
Dog Number Total Cells, x 10' Purity, " Total Cells, x 10' Purity, " Total Cells, x 10' Total Cells, x I0'
E536 3 (O.21kg) 98 12 (0.821kg) 99.2 4.3 (0.29/kg/kg) 5 (0.34/kg)
E563 2.76 (0.17/kg) 97 4.2 (0.26/kg) 99 2.97 (0.18/kg) 2.35 (0. I4/kg)
E694 4 (0.4/kg) 99 12.8 (1.28/kg) 98 4 (0.4/kg) 2 (O.21kg)
E658 NO NO 8 (0.67/kg) 99.5 1.94 (0.15/kg)
E728 NO NO 18.4 (1.47/kg) 100 6.53 (0.521kg)
Mean 3.25 (0.25/kg) 98 11.08 (0.9/kg) 99.1 US (O.29/kg) 3.56 (O.271kg)
-ND indicates not done.
(cSCF), canine granulocyte colony-stimulating factor
(cG-CSF), and protamine sulfate (8 ug/ml.) and incubated
for 2 days at 37°C in a 95% 02' 5% CO2atmosphere. After
2 days of culture, nonadherent and adherent cells, including
irradiated packaging cells, were counted, pooled, and
infused intravenously into the dogs within 24 hours of TBI.
LN and LNY vectors carry the bacterial neomycin phos-
photransferase (neo) gene conveying G418 resistance and are
identical with the exception of different length sequences
between the neo gene and the vector 3' long-terminal
repeats. This allows the use of a single pair of polymerase
chain reaction (PCR) primers to amplify both sequences and
distinguish them by gel electrophoresis. Thus, cells derived
from the cell populations that are genetically marked with
both vectors could be detected and quantitated from the
same blood and marrow samples.
Analysis of neo Gene Expression by Colony Forming
Unit-Cell Assay
Following transduction, aliquots from CDH+Lin- and
CDH-Lin- cell populations were resuspended in culture
medium (a minimal essential medium supplemented with
40% FBS, 2% bovine serum albumin [Fisher Biotech, Fair
Lawn, NJ]) and cultured in a 2-layer agar culture system
[17,20,24] containing erythropoietin (4 IU/mL), cG-CSF,
cSCF, and canine granulocyte/macrophage colony-stimulating
factor (cGM-CSF), each at 100 ng/mL (kindly provided by
Amgen, Thousands Oaks, CA). CDH+Lin- and CDH-Lin-
cells were plated in duplicate at 10 x 103 and 50 x 103 cells,
respectively, per 35-mm plasticculture dish (Falcon). Colonies
grown with and without G418 (0.5-0.6 mg/mL) were counted
after a 14-day incubation at 37°C in a 95% 02' 5% CO2
atmosphere. Untransduced control cellswere plated after sort-
ingwith the same G418 concentrations.
Detection of neo Gene by PCR
Genomic DNA was extracted from blood cells every
1 or 2 weeks from engraftment to 6 months after transplan-
tation, and then monthly. DNA was also isolated from
monocytes, granulocytes, and T cells purified by cell sorting
at several time points after transplantation. PCR condi-
tions for amplifying the LN and LNY vectors have been
described [20,22]. Briefly, 500 ng of genomic DNA were
amplified with LN(SN) 225'7 and LN(ASN) 3210 primers
using the following PCR conditions: denaturation at 95°C,
followed by 31 cycles of 62°C annealing (l min), and 95°C
denaturation (1 min) with a final extension at noc for
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7 minutes. PCR reactions were run in the presence of
10 ~Ci/mL 32p deoxycytidine triphosphate, and the PCR
products were separated on a 6% polyacrylamide gel.
RESULTS
Enrichment and Transduction of CD34+Lin- and
CD34-Lin- Cells
Mean yields of sorted CDH+Lin- cells and CDH-Lin-
cells were 0.25 x 106/kg (range, 0.2-0.4 x 106/kg) and 0.9 x
106/kg (range, 0.26-1.47 x 106/kg), respectively, with mean
purities of 98% (range, 97%-99%) and 99% (range, 98%-
100%), respectively (Table 1, Figure 1). Cell viability after
sorting was >98% by trypan blue assay. After the 48-hour
transduction period, the numbers of CDH+Lin- cells were
slightly increased, with a mean cell recovery of 3.75 X 106
(range, 2.97-4.3 x 106) (0.29 x 106/kg [range, 0.18-0.4 x
106]). There were substantial decreases of CDH-Lin- cells
after transduction, with a mean cell recovery of 3.56 x 106
(range, 1.94-6.53 x 106) (0.27 X 1061kg [range, 0.14-0.52 x
106]). This is consistent with previous findings showing that
the reduction in cell numbers is inversely correlated with
initial CD34+cell content [22]. Gene transfer efficiencies of
transplanted cells, evaluated by the growth of neo resistant
colony-forming unit cells (CFU-Cs), ranged from 6% to
18% in the CDH+Lin- cells, whereas no neo resistant CFU-C
formation was observed in the CDH-Lin- cells (Table 2).
Autologous Transplantation
Three dogs (£536, E563, E694) received transplants of
both CD34+Lin- (doses reinfused: 0.29 x 106/kg, 0.18 x
106/kg, and 0.4 x 106/kg, respectively) and CDH-Lin- cells
(doses reinfused: O.H x 106/ kg, 0.14 x 106/kg, and 0.2 x
106/kg, respectively) (Table 3). Given the expected low doses
of transduced cells infused, nontransduced cryopreserved
marrow cells (£536, E563, E694) or CDH- enriched cells
(£658, E728) were given to ensure hematopoietic recovery
(Table 3). All dogs engrafted, with neutrophil counts
>50011lL and platelet counts >20,0001IlL achieved at medians
of day 14 and day 30, respectively (Table 3). At a median fol-
low-up of 12 months (range, 11-14 months), all dogs were
aliveand well, with blood counts within normal ranges.
Detection of Transduced Cells After Transplantation
LN vector-containing cells (from CD34+Lin- cells)were
detected at engraftment and up to 12 months posttransplanta-
tion in 3 of 3 dogs (£536, E563, E694) at a median follow-up
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Figure I. Enrichment and depletion of CD34POS cells. In each experiment, Ficoll-separated marrow mononuclear cells were divided into 2 frac-
tions, enriched or depleted of CD34+ marrow cells, by cell sorting. Samples from the sorted fractions were analyzed to evaluate the degree of purity
of both CD34+Lin- and CD34-Lin- marrow cells before retroviral transduction. The top panels show enrichment (>97%) of CD34+ marrow cells
and depletion (100%) of monocytes (CD14+) and lymphocytes (CDn from dog E563. The bottom panels show depletion (>99%) of both CD34+
marrow cells and lineage committed marrow mononuclear cells.
of 13 months (range, 11-14 months). Transduced cells were
more frequently detected during the first 2 months post-
transplantation than at later time points (Figure 2). The gene
transfer efficiency fluctuated throughout the follow-up from
0% to 10% (Figure 2). LNY vector--eontaining cells (from
CD34-Lin- cells) were not detected at any time after trans-
plantation in any of the 5 dogs, with a median follow-up of
12 months (range, 11-14 months).
To evaluate if transduced CD34+Lin- marrow cells were
contributing to multilineage long-term hematopoiesis, gran-
ulocytes, monocytes, and T cells were purified by FACS
from 2 dogs at 7.5 months (E694) and 9 months (E563)
after transplantation. In a third dog (E536), granulocytes
were obtained at 12 months after transplantation. These
dogs were studied because transduced cells were previously
detected in unfractionated peripheral blood. LN vector-
containing cells were detected in each cell population from
each dog (Figure 3), and LNY vector--eontaining cells were
not detected in any of the sorted samples.
DISCUSSION
Human CD34+ cells, which are thought to have long-
term hematopoietic engrafting potential, have been targets
for preclinical and clinical gene therapy protocols employ-
ing retroviral vectors [25-33]. In other clinical studies,
enriched populations of CD34+cells have reliably provided
sustained multilineage hematopoiesis after transplant [34-
38]. However, investigators have recently reported that the
most primitive hematopoietic stem cell may lack the expres-
sion of CD 34 [9,14,39]. Most in vivo studies addressing this
question have involved murine models, including, in some
cases, experiments in which the cell progeny derived from a
single progenitor cell could be evaluated [9]. Similar experi-
ments are not possible in large animals such as the dog
because single cells cannot provide radioprotection [17].
In this study, employing a standard CFU assay, based on
the formation of neo resistant colonies after 10 to 14 days of
culture on semisolid medium, we could detect transduced
marrow CD34+Lin- cells from all dogs but not transduced
marrow CD34-Lin- cells. The fact that we did not detect
LNY vector--eontaining blood cells in vitro and in vivo after
transplantation could be multifactorial. First, we employed
culture conditions that appear to provide for efficient trans-
duction of unmodified bone marrow and CD34+-enriched
marrow cells [22,23]. Because transduction of CD34- pro-
genitors may require different culture conditions for optimal
transduction, this could be an important limitation. Naka-
mura et aI. recently showed that CD34+cells with reconsti-
tuting abilities were derived from CD34-Lin- cells only after
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Table 2. Transduaion Efficiency by Neomycin (G418) Resistant CFU-CAssay ofCD34+Lin- andCD34 Lin- Marrow Cells After a 2-DayPeriod of
Cocultiuation onIrradiated PGI3-Based Packaging Cells"
Number of CFU-C Number of CFU·C G418 Number of CFU-C G418 Transduction
Dog Number Control (No G418) at 0.5 mglmL at 0.6 mg/mL Efficiency, "
E536
Sorted CD34+L1n' 348/286 15130 24114 7.1/6
Sorted CD34""Lln- 011 0/0 0/0 0/0
E563
Sorted CD34+Lln- II/II 3/5 2/2 36118
Sorted CD34""Lln- 3/3 0 011 (c1uster)t Olt
Untransduced sorted CD34+L1n- 32/63 1/1 0/0
E694
Sorted CD34+L1n- 7/9 , 1/2 011 18/6.25
Sorted CD34-L1n- 21/13 0/0 0/0 0/0
E658
Sorted CD34-L1n' 0/0 010 0/0 0/0
E728
Sorted CD34""Lln- 010 010 0/0 010
"Cells were plated at 10,000 CD34+Lin- per plate and 50,000 CD34-Lin- per plate.
tPossible contamination of a transduced differentiated cell with CFU-C activity.
4 days of culture on irradiated murine stromal cell layers
[14].The combination of eytokines used to induce differenti-
ation of CD34-Lin- cells into CD34+cells differed from the
one used in most transduction protocols for CD34+cells [14].
Moreover, retroviral vectors require cycling of target cells to
permanently insert genes into mammalian cells. Second, it is
possible that the CD34-Lin- cell doses (mean, 4.53 x 106/kg)
obtained after sorting were too low to retain detectable
transduced cells with reconstituting abilities. In previous
autologous transplant experiments, we found that doses of
107/kg of CD34+-depleted marrow cells were not radiopro-
tective after myeloablative conditioning, even when contain-
ing a small admixture of CD34+ cells [17]. Given the lack
of detectable engraftment from CD34-Lin- cells in the first
3 dogs, we transplanted 2 additional dogs with CD34- cells
and provided support by untransduced CD34+-enriched
marrow cells to reduce the number of unmodified marrow
CD34-Lin- cells that may have reduced the ability to detect
progeny of transduced CD34-Lin- cells. These 2 experi-
ments again provided no evidence of mature blood cells
derived from the CD34-Lin- fraction.
In our model, the high purity of the sorted cells together
with the detection of LN vector-eontaining blood cells in
the early and late posttransplantation periods provided
strong evidence that transduced CD34+Lin- cells contributed
to both short- and long-term engraftment. Moreover, the
detection of engraftment from relativelysmall doses of trans-
duced CD34+ cells (mean of total cultured cells reinfused,
0.29 x 106/kg), which by themselves might not be radiopro-
tective, was not prevented by the simultaneous infusion of
much higher doses (mean, 228 x 106/kg) of untransduced
bone marrow cells. This may suggest, as previously shown
in mice, that the neo resistant cells did not have a signifi-
cant proliferative disadvantage over untransduced cells [40].
Table J. Autologous Transplants with CD34+Lin- andCDJ-rLin- Marrow Cells After 920 cGy TBI: Engraftment Kinetics and Detection of
Vector-Containing Cells"
E658 E728
0.15 0.52
0.79 1.28
15 II
20 12
27 32
CD34+L1n' marrow cells, x IO'/kg Infused
CD34-L1n' marrow cells, x I O'/kg Infused
Untransduced cryopreserved bone marrow cells, x 10'/kg Infused
Untransduced cryopreserved enriched CD34+ marrow cells, x I O'/kg Infused
Days to granulocytes >500/J.1L
Days to granulocytes> IOOOllll
Days to platelets >20,OOO/J.1L
Detection of LN vector-contalnlng cells
White blood cells
Lymphocytes
Granulocytes
Monocytes
Detection of LNY vector-contalning cells
White blood cells
·NT indicates not tested.
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Dog Number
E536 E563 E694
0.29 0.18 0.4
0.34 0.14 0.2
0.48 0.045 0.16
13 17 14
14 19 16
38 30 23
Yes Yes Yes
NT Yes Yes
Yes Yes Yes
NT Yes Yes
No No No No No
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FllUre 1. Representative molecular analysis by PCR performed at different time points during the study. Overall, LN vector-containing cells were
detected up to 12 months posnransplantation in 3/3 dogs given CD34+Lin- cells. Asshown in the figure, successfully transduced cells were more
frequently detected during the first 2 months after transplantation than at later time points. LNY vector-containing celIs, from CD34-Lin- cells,
were not detected at any time after transplantation in any of the 5 dogs.
Previous studies had shown that progeny of retrovirally
transduced canine bone marrow cells could be detected for
up to 5 years posttransplantation, indicating transduction of
long-term repopulating progenitors. Our findings suggest
that transduction of CD34+ cells and not CD34- cells was
most likely responsible for those prior observations [41].
Transduced cells were more frequendy detected during
the first 2 months posttransplantation than at later time
points. This observation might have several explanations.
First, the transduced CD34+Lin- cells are likely a heteroge-
neous population at different stages of lineage commitment.
Early repopulation may have come from more easily trans-
duced committed progenitors followed by their exhaustion.
Second, clones with higher self-renewal and differentiating
abilities may have emerged later after transplantation and
contributed to long-term engraftment. Third, these observa-
tions could reflect a stochastic process of progenitor cell acti-
vation, as postulated in computerized models and murine
studies, which defined a concept of clonal succession [42-45].
Furthermore, murine studies showed that after a period of
2 to 6 months, a few clones with high reconstituting potential
gave rise to long-term hematopoiesis, and results from a cat
model suggested an initial phase of clonal disequilibrium, fol-
lowed by stable hematopoiesis maintained by single or few
clones with high self-renewal and proliferative potentials
[46-51].Longer follow-up of the fate of the transduced cells in
these dogs may give new insights into the in vivo life span of
small doses of retrovirally transduced CD34+ hematopoietic
progenitor cells and their contribution to hematopoiesis.
To assess the contribution to long-term engraftment in
different lineages, T cells, monocytes, and granulocytes
were studied by PCR at 7, 9, and 12 months posttransplan-
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tation. In 2 dogs studied, all 3 sorted populations contained
vector-transduced cells.The ability of human and nonhuman
primate CD34+hematopoietic progenitor cells to differenti-
ate into both lymphoid and myeloid progeny was previously
demonstrated by transduction with retroviral vectors and
the use of proviral integration analysis [52,53].
In murine studies, a "side population" defined by
Hoechst 33 342 staining appears to contain primitive
hematopoietic progenitors that may differentiate into
CD34+ cells [11]. Studies on human side population cells
FllUre J. To evaluate if transduced CD34+Lin- marrow cells were
contributing to multilineage long-term hematopoiesis, DNA was
extracted from granulocytes (DM5+), monocytes (CD14J, and T cells
(Cm+) purified by celI sorting from 2 dogs at 7.5 months (E694) and 9
months (E563) after transplantation. peR analysis showed that all
sorted fractions contained cells carrying the LN vector used to trans-
duce CD34+Lin- marrow celIs. LNY vector-containing cells were not
detected in any of the sorted samples.
have not provided conclusive evidence of the existence of
primitive multilineage progenitors in the side population,
suggesting possible interspecies differences. Results similar
to our study were recently reported in a primate model, in
which repopulating cells were derived from marrow CD34+
and not from CD34- cells [54]. However, an important dif-
ference in that study was the use of growth factor treatment
before collection of marrow. Because the effect of in vivo
growth factors on CD34 expression in primates is unknown
and because CD34 may be an activation marker, its expres-
sion on progenitors may be altered by growth factor expo-
sure. Also, expansion of the CD34+progenitor compartment
could reduce the frequency of rare CD34- progenitor cells
in marrow harvests. Notwithstanding these concerns, the
primate study failed to detect CD34- progenitor cells.
The dog remains an important preclinical model for
hematopoietic cell transplantation and gene therapy proto-
cols. Canine genetic diseases, such as mucopolysaccharidosis
[55], pyruvate kinase deficiency [56], and phosphofructoki-
nase deficiency [57], could potentially be cured with the
achievement of long-term engraftment of hematopoietic
progenitor cells transduced with a functioning gene. This
study has provided evidence that highly purified canine
CD34+ cells can provide long-term multilineage repopula-
tion after myeloablative TBI. These findings are potentially
important for future preclinical studies of canine hemato-
poiesis and hematopoietic cell transplantation and may also
be relevant as a model for human hematopoiesis. They also
support a rationale for targeting bone marrow CD34+cells
in gene therapy studies that aim to transduce long-term
repopulating hematopoietic cells. Canine CD34-Lin- cells
with short- or long-term repopulating function were not
detected. However, because no evidence of in vitro trans-
duction was demonstrated with this experimental design,
our results did not exclude a biologically relevant contribu-
tion of CD34-Lin- cells to posttransplantation hemato-
poiesis in these animals. However, previous experiments
with CD34+-depleted cell grafts together with studies of
CD34+ purified grafts [17] appear to exclude a significant
role for CD34- progenitor cells in hematopoietic recovery
early after myeloablative therapy. Any role for CD34- stem
cells in canine hematopoiesis might be more readily
detected in studies that employ ex vivo gene marking with
adenoviral vectors that do not require cell cycle for integra-
tion [58-60] or with allogeneic transplants of purified
CD34- cell grafts into immunodeficient mice or dogs.
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